Navigation Links
Pharma ChemOutsourcing Targets BioNJ, PA Bio, MassBio, BayBio, SoCalBio, and NY Biotechnology Association Member Companies for September 2011 Show in New Jersey
Date:3/1/2011

LONG BRANCH, N.J., March 1, 2011 /PRNewswire/ -- Pharma ChemOutsourcing today announced that it would offer a special rate to select member companies of the USA's various state biotechnology associations to help make the event financially accessible to all those who would like to attend the September 12-15 show in New Jersey.

"We have all witnessed the explosive growth of hundreds of successful biotechnology companies over the past 12 years. Many of them already attend or speak at Pharma ChemOutsourcing's annual event and many more would benefit. This year we want to be sure that everyone knows about the opportunity and takes advantage of it. So we have implemented a special rate until May 15, 2011 to make it possible," remarked Mark Alexay, Pharma ChemOutsourcing's President. Details may be found at http://chemoutsourcing.com/biotech.php

"The biotech attendees return to the show year after year, tell us it's a great place to network, talk about chemistry, and meet their suppliers. Our goal is to continue to mold the show into a special annual event for pharmaceutical chemists. With biotech's ascending role in the discovery and development of new therapeutics, now is the time to further tailor the show to meet their changing needs." The list of the first 50 biotech speakers for the September 12-15, 2011 show is at http://chemoutsourcing.com/speakers.php

"Our ultimate goal is to attract chemists from every emerging and medium-sized pharmaceutical company in the world – The USA is the world leader in biotechnology – so facilitating quality interactions among its leader at the event is good for business. Pharma ChemOutsourcing's niche is for R&D management. We bring together large numbers of medicinal and process chemists, plus chemical development. In 2010 we attracted about 800 attendees. The value of the show will grow if
'/>"/>

SOURCE Pharma ChemOutsourcing
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... Calif. , May 21, 2013 Abaxis, ... blood analysis systems, announced today that Martin ... at the Stifel Annual Dental & Veterinary Conference on ... conference will be held at Le Parker Meridien Hotel ... About Abaxis Abaxis develops, manufactures, markets ...
(Date:5/21/2013)... JUPITER, Fla. , May 21, 2013  BioRestorative ... a life sciences company focused on developing stem cell ... Mark Weinreb , its President and CEO, ... The conference will be held on Thursday, ... at 109 E 42nd Street in New York City.  ...
(Date:5/21/2013)... 2013 Ceregene, Inc. today announced additional ... double-blind, randomized, controlled Phase 2b clinical study of ... designed to deliver the neurotrophic factor neurturin, for ... robust response to CERE-120 in Parkinson,s patients diagnosed ... those diagnosed 10 years or more (p<.005), as ...
Breaking Medicine Technology:Abaxis, Inc. to Present at the Stifel Annual Dental & Veterinary Conference 2BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference 2BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference 3Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 2Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 3Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 4Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 5
... Nov. 18, 2010 The Pharmacy Technician ... Melissa Murer Corrigan, will serve as the 2011 president ... be installed at the ICE Annual Education Conference on ... organization that provides educational, networking and advocacy resources for ...
... 2010 Cell Therapeutics, Inc. ("CTI") (Nasdaq and ... Application ("MAA") seeking approval for Pixuvri™ (pixantrone dimaleate) ... relapsed or refractory aggressive non-Hodgkin,s lymphoma ("NHL") was ... Medicines Agency ("EMA"). Validation indicates that the application ...
Cached Medicine Technology:Melissa Murer Corrigan to Serve as 2011 ICE President 2The European Medicines Agency Validates and Accepts Cell Therapeutics' Marketing Authorization Application for Pixuvri™ 2The European Medicines Agency Validates and Accepts Cell Therapeutics' Marketing Authorization Application for Pixuvri™ 3
(Date:5/21/2013)... May 21 (HealthDay News) -- Urban elementary school ... experience sleep problems and suffer academically, new research ... aged seven to nine, we found that compromised ... and impaired academic performance," said study author ... human behavior at Brown University,s Alpert Medical School ...
(Date:5/21/2013)... Minn. Positively charged gold nanoparticles are usually ... to avoid nanoparticle toxicity. Mayo Clinic researchers found ... nanoparticles effective against ovarian cancer cells. The discovery ... the Journal of Biological Chemistry ., "This ... cancer cells by preventing the cell death or ...
(Date:5/21/2013)... May 21, 2013 Representatives with Hammerhead Bicycles ... a success that the company has achieved its overall goal ... day one was to move Hammerhead Bicycles from a house ... President Scott Robertson. , Robertson explained that the bike shop ... to exclusively focus on all things 29er and 650b. ...
(Date:5/21/2013)... the sound of galloping hooves behind you, your immediate reaction ... it is actually a zebra approaching. Doctors are trained to ... their practices, and as they rarely or never meet a ... takes many years to reach the right diagnosis. A new ... many cases. , Ole Winther is Associate Professor at ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 Two-thirds of ... non-small cell lung cancer reported that they engage in ... medicine use, according to new findings from the ... Kantar Health . The research will be presented ... (International Society for Pharmacoeconomics and Outcomes Research) in New ...
Breaking Medicine News(10 mins):Health News:Sleepless Nights May Hurt School Performance of Kids With Asthma 2Health News:Mayo Clinic: How gold nanoparticles can help fight ovarian cancer 2Health News:Hammerhead Bicycles Now a Standalone Brand 2Health News:New search engine finds rare diagnoses 2Health News:New search engine finds rare diagnoses 3Health News:Two in Three Cancer Patients are Non-Adherent with Their Medications, According to Kantar Health Research 2Health News:Two in Three Cancer Patients are Non-Adherent with Their Medications, According to Kantar Health Research 3
... Leuven - Jean-Christophe Marine (VIB, K.U.Leuven) strongly argues against the ... long time - been seen as an attractive drug target ... as a tumor suppressor, and thus inhibits tumor formation. His ... cancer drug targets. Tumorigenesis: loss of control ...
... March 15, 2011 Minor league hockey players in the ... a brain injury since bodychecking was first allowed among the ... Hospital neurosurgeon Dr. Michael Cusimano. The findings, published online ... growing evidence that bodychecking holds greater risk than benefit for ...
... by today,s high throughput DNA sequencing technology presents a ... handle the staggering amount of data, and, more importantly, ... experiment? Aside from the cost of the sequencing platforms ... to expand hardware and storage resources, but getting to ...
... carcinoma (HCC) have been increasing worldwide, and hepatitis ... in the pathogenesis of HCC. Previous studies have ... consumption, smoking, diabetes mellitus, and obesity, are important ... reported that HCV infection causes insulin resistance and ...
... well reported complication in chronic cholestatic liver disease such as ... deficiency has been addressed in many articles over the last ... alcoholic liver cirrhosis. A research article published on February ... addresses this question. The authors described the serum vitamin D ...
... Steven Reinberg HealthDay Reporter , MONDAY, March 14 ... not clear, but it now appears that it may be ... before it becomes evident, a new study suggests. This ... seen in people who do not develop Alzheimer,s disease, the ...
Cached Medicine News:Health News:New insights into cancer treatment 2Health News:Brain injuries rise sharply in minor hockey after bodychecking rules relaxed: Study 2Health News:mygenomatix: A secure cloud-like model for next-gen sequencing data analysis 2Health News:Mental Decline May Start Years Before Alzheimer's 2
... a Q-switched ruby laser system ... nm. High Performance Combined with ... combination of high performance and ... mode effectively destroys the (natural ...
A Powerful New Quantitative Immunoassay for Monitoring Bladder Cancer Patients. Useful in Monitoring Patients for,Disease Progression and Recurrence....
... Test is an in vitro immunoassay intended for ... tumor associated antigen. It is indicated for use ... cancer in conjunction with cystoscopy or when prescribed ... by the FDA for prescription home use in ...
... is a quantitative microplate enzyme immunoassay that detects ... have very small amounts of NMP22 protein in ... is often elevated in the urine of patients ... the disease. The use of the NMP22 protein ...
Medicine Products: